|
|
Start year |
End year |
Title |
Source |
Position |
| 1. |
|
2010 |
2012 |
Investigator |
NIH |
Abrogation of Human CD59 Function for Immune Cancer Therapy |
| 2. |
|
2011 |
|
Investigator |
NIH |
Atherogenic roles of complement membrane attack complex |
| 3. |
|
2011 |
|
Investigator |
Leukemia $ Lymphoma Society |
To develop a therapeutic CD59 inhibitor for treating B-cell malignancies |
| 4. |
|
2011 |
|
Investigator |
NIH |
A universal model for cell ablation |
| 5. |
|
2011 |
|
Investigator |
NIH |
Hemolysis-associated sudden death and/or fatal pulmonary hypertension |
| 6. |
|
2010 |
|
Investigator |
American Heart Association |
Inhibition of complement activation for the treatment of atherosclerosis |
| 7. |
|
2008 |
2010 |
Investigator |
Harvard University Technology Development Accelerator Fund |
Abrogation of Human CD59 Function for Immune Cancer Therapy |
| 8. |
|
2005 |
2010 |
Investigator |
NIH |
Towards a Mouse Model of Complement-Mediated Diseases |
| 9. |
|
2004 |
2008 |
Investigator |
American Heart Association# 0435483N |
Role of Complement in the Pathogenesis of Atherosclerosis Scientific Development Program |
How We Rank
